Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome

Pediatr Blood Cancer. 2019 Jan;66(1):e27492. doi: 10.1002/pbc.27492. Epub 2018 Sep 30.

Abstract

Patients with Beckwith-Wiedemann spectrum (BWSp) undergo quarterly alpha-fetoprotein measurement for hepatoblastoma (HB) screening up to 4 years of age, paralleling the epidemiology of nonsyndromic HB. However, specific data on the timing of HB development in BWSp are lacking. Here we compare the timing of presentation of HBs in BWSp with a control cohort of consecutive HB cases, demonstrating that halving screening duration of screening procedures in BWSp likely will not impact its effectiveness.

Keywords: Beckwith-Wiedemann; alpha-fetoprotein; cancer screening; hepatoblastoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Beckwith-Wiedemann Syndrome / physiopathology*
  • Child, Preschool
  • Early Detection of Cancer / standards*
  • Female
  • Follow-Up Studies
  • Hepatoblastoma / diagnosis*
  • Hepatoblastoma / epidemiology
  • Hepatoblastoma / metabolism
  • Humans
  • Infant
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / epidemiology
  • Liver Neoplasms / metabolism
  • Male
  • Prognosis
  • Retrospective Studies
  • Time Factors
  • alpha-Fetoproteins / metabolism*

Substances

  • alpha-Fetoproteins